Cardiac allograft vasculopathy (CAV) affects approximately 30% of cardiac transplant patients at 5 years post-transplantation. To date, there are few CAV treatment or prevention options, none of which are highly effective. The aim of the study was to investigate the effect of thalidomide on the development of CAV. The effect of thalidomide treatment on chronic rejection was assessed in rat orthotopic aortic transplants in allogeneic F344 or syngeneic Lew rats (n = 6 per group). Animals were left untreated or received thalidomide for 30 days post-transplant, and evidence of graft CAV was determined by histology (trichrome and immunohistochemistry) and intragraft cytokine measurements. Animals that received thalidomide treatment post-transplant showed markedly reduced luminal obliteration, with concomitant rescue of smooth muscle cells (SMCs) in the aortic media of grafts. Thalidomide counteracted neointimal hyperplasia by preventing dedifferentiation of vascular SMCs. Measurement of intragraft cytokine levels after thalidomide treatment revealed downregulation of matrix metalloproteinase 8 and monocyte chemotactic protein 1, cytokines involved in tissue remodelling and inflammation, respectively. Importantly, no negative side effects of thalidomide were observed. Thalidomide treatment prevents CAV development in a rodent model and is therefore potentially useful in clinical applications to prevent post-transplant heart rejection.
SUMMARY
Cardiac allograft vasculopathy (CAV) affects approximately 30% of cardiac transplant patients at 5 years post-transplantation. To date, there are few CAV treatment or prevention options, none of which are highly effective. The aim of the study was to investigate the effect of thalidomide on the development of CAV. The effect of thalidomide treatment on chronic rejection was assessed in rat orthotopic aortic transplants in allogeneic F344 or syngeneic Lew rats (n = 6 per group). Animals were left untreated or received thalidomide for 30 days post-transplant, and evidence of graft CAV was determined by histology (trichrome and immunohistochemistry) and intragraft cytokine measurements. Animals that received thalidomide treatment post-transplant showed markedly reduced luminal obliteration, with concomitant rescue of smooth muscle cells (SMCs) in the aortic media of grafts. Thalidomide counteracted neointimal hyperplasia by preventing dedifferentiation of vascular SMCs. Measurement of intragraft cytokine levels after thalidomide treatment revealed downregulation of matrix metalloproteinase 8 and monocyte chemotactic protein 1, cytokines involved in tissue remodelling and inflammation, respectively. Importantly, no negative side effects of thalidomide were observed. Thalidomide treatment prevents CAV development in a rodent model and is therefore potentially useful in clinical applications to prevent post-transplant heart rejection.
Introduction
Over the past several decades, patient survival after heart transplantation has improved; however, most of this benefit has accrued during the early period posttransplantation while long-term survival is still compromised by complications such as chronic cardiac allograft rejection, otherwise known as cardiac allograft vasculopathy (CAV). This form of chronic rejectionoccurring months to years post-transplant -affects more than 30% of patients at 5 years post-transplant [1] [2] [3] . CAV is a highly aggressive form of coronary artery disease [4] caused by a combination of immune and nonimmune responses that result in characteristic narrowing of donor coronary arteries, although the exact mechanisms remain unclear. Of the few treatment options available for CAV, most focus on prevention and none are particularly effective [5] . To this date, the only treatment option for patients with CAV associated with longer lifespan is re-transplantation, which carries a higher risk compared to the original transplant [6] .
Thalidomide was originally introduced as a therapy for morning sickness in pregnant women, but was soon removed from the market due to its teratogenic effects [7] . However, thalidomide has since been repurposed as an immunomodulator and has been approved for use as a treatment for multiple diseases, including multiple myeloma and erythema nodosum leprosum [8] [9] [10] . Thalidomide's anti-inflammatory and immunomodulatory functions as well as its beneficial effect on chronic graft-versus-host disease after bone marrow transplantation make it an ideal candidate for preventing graft rejection [11] . Indeed, thalidomide alone or low levels of thalidomide and cyclosporine can be used to reduce rejection of cardiac allografts in rabbits [12] , and thalidomide has been found to lessen neotintimal thickness after aortic graft transplantation [13] . However, the mechanism by which thalidomide reduces rejection rates remains unknown, with reports conflicting regarding its effects on inflammatory cells, vascular pericytes and SMCs.
Here, we show effects of thalidomide treatment in a chronic rat orthotopic (Male Fischer 344:Male Lewis) aortic transplantation model. Thalidomide dramatically reduces the development of intimal thickening by rescuing SMC numbers, differentiation and localization. Intragraft cytokine levels were measured to further determine thalidomide's possible mechanisms of action.
Materials and methods

Animals
All animals were purchased from Charles River Laboratories (Bad Sulzfeld, Germany) and received care in compliance with the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 86-23, revised 1996). Studies were approved by the local ethical committee 'Hamburg Amt f€ ur Gesundheit und Verbraucherschutz'.
Orthotopic aortic transplantation (chronic CAV study)
Orthotopic aortic transplantation was performed as previously described [14] . Briefly, a section of the thoracic aorta from F344 (allogeneic) or Lew (syngeneic) was orthotopically transplanted into the infra-renal abdominal aorta of Lew rats via an end-to-end anastomosis. Three groups (n = 6 animals per group) were randomly assigned to receive either 100 mg/kg/day of thalidomide p.o. or vehicle control.
Heterotopic heart transplantation (acute study)
Heterotopic heart transplantation was performed as previously described [15] . Briefly, BN (allogeneic) and Lew (syngeneic) hearts were heterotopically transplanted to the abdominal great vessels of Lew rats. Three groups (n = 6 animals per group) were randomly assigned to receive either 100 mg/kg/day of thalidomide p.o. or vehicle control. Six days post-transplant, animals were euthanized, the apical half of the graft was snap frozen for cytokine quantification, and the caudal part was fixed (4% paraformaldehyde) for further tissue processing.
Histopathology
Harvested grafts were fixed (4% paraformaldehyde), dehydrated and embedded in paraffin. Each block was sectioned into 5-lm sections followed by trichrome staining using the manufacturer's protocol (SigmaAldrich, St. Louis, MO, USA) for evaluating luminal occlusion and immunofluorescence. Luminal obliteration was quantified, using IMAGEJ (Bethesda, MD, USA) as follows: Vascular occlusion (%) = [Area of intima/ (Area of intima + Vascular lumen)] 9 100. Three sections were analysed from each aortic allograft, and results were averaged.
Immunofluorescence staining
Paraffin sections underwent heat-induced antigen retrieval with Dako antigen retrieval solution (Dako, Glostrup, Denmark) followed by blocking with ImageiT FX signal enhancer (Invitrogen, Carlsbad, CA, USA). Primary antibodies were used as appropriate: smooth muscle actin (SMA) (ab5694), smooth muscle heavy chain (SMHC) (ab124679) or embryonic smooth muscle heavy chain (SMemb) (Yamasa 7602). A mouse irrelevant IgG1 (Abcam, Cambridge, UK) was used as negative control. Secondary antibodies were Alexa Fluor 488 or Alexa Fluor 555 (Invitrogen). Imaging was performed using a Nikon Eclipse TiE microscope equipped with the Perkin Elmer UltraVIEW VoX confocal imaging system. Analysis was carried out with VOLOCITY 6.1.1 (Perkin Elmer, Waltham, MA, USA).
Side effect screening
Serum was obtained prior to animal sacrifice in order to investigate the effect of thalidomide on blood cholesterol, triglycerides, kidney, liver and blood count.
Cytokine antibody array
Cytokine antibody arrays of homogenized grafts were performed according to the manufacturer's protocol (RayBiotech, Norcross, GA, USA). Membranes were digitized using bioluminescence imaging and quantified using IMAGEJ. Cytokine concentrations are expressed in arbitrary units (AU).
Unidirectional ELISpot assay
Recipient splenocytes (responder cells) were isolated from fresh spleen 6 days after heart transplantation. 1 9 10 6 donor stimulator cells were incubated with 1 9 10 6 responder cells for 24 h. IFNc spot frequencies were assessed in quadruplicate using an automatic counted ELISpot plate reader (CTL, Cincinnati, OH, USA).
CFSE-MLR proliferation assay
The carboxyfluorescein succinimidyl ester-mixed lymphocyte reaction (CFSE-MLR) was performed with the acute heterotopic transplantation study animals. Briefly, responder and stimulator cells were co-cultured at equal ratios (3 9 10 6 /ml) in a 48-well plate for 5 days at 37°C, 5% CO 2 in RPMI 1640 medium (Gibco, Darmstadt, Germany) supplemented with 1% penicillin/streptomycin solution, 10% FCS and 50 lM b-mercaptoethanol (ES-007-E; Millipore, Darmstadt, Germany). Cells were harvested and analysed by flow cytometry, gating for intensity of CFSE fluorescence. Stimulation index (SI) was calculated based on the mean value of each animal.
Statistics
Data are presented as mean AE standard deviation. Comparisons within groups used analysis of variance with Bonferroni or LSD post hoc tests, as appropriate. Probability values (P) less than 0.05 were considered significant. Statistical analysis was performed using SPSS statistical software package 15.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Thalidomide treatment reduces luminal obliteration in chronic rejection model
We measured the effect of thalidomide on intimal thickening in a chronic low responder model using an accepted orthotopic aortic transplantation model for CAV [14, 16] . Syngeneic transplants were performed as a procedural control. Allogeneic transplants were given either vehicle control or 100 mg/kg thalidomide by oral gavage for 30 days post-transplant (Fig. 1a) .
As expected, syngeneic grafts showed no signs of cellular rejection in histology and exhibited minimal levels of luminal obliteration (1.32%) as compared to vehicletreated allogeneic grafts (21.27%). Strikingly, animals treated with thalidomide showed marked reduction in luminal occlusion (6.76%, P < 0.001) (Fig. 1b/c) , suggesting that thalidomide may be a viable option for preventing CAV.
SMCs of the aortic media are maintained by thalidomide in CAV model
Staining for smooth muscle actin (SMA) confirms that the aortic media of syngeneic grafts is largely comprised of mature SMCs (Fig. 2a) . A strong reduction in medial SMA intensity was found in vehicletreated allogeneic grafts, an effect that was prevented by thalidomide treatment. Quantification of immunohistochemical images confirmed these observations (Fig. 2c) .
To clarify SMC differentiation levels in each model, we compared smooth muscle cell heavy chain (SMHC; marker for differentiated SMCs) and embryonic smooth muscle heavy chain (SMemb; marker for dedifferentiated SMCs) intensities (Fig. 2b/c) The syngeneic model shows low base levels of obliteration (mean = 1.34%), which is strongly increased in the allogeneic no medication control (mean = 21.27%) and strikingly mitigated upon treatment with thalidomide (mean = 6.76%; P < 0.001). Error bars indicate mean AE SD. *P < 0.05. levels with a corresponding increase in differentiated medial SMCs.
Thalidomide treatment alters intragraft cytokine release profile
To investigate the mechanism by which thalidomide affects the proliferative and pathological features of CAV, we examined expression of key cytokines/chemokines induced in allogeneic graft transplantation (Fig. 3) .
Cytokine protein arrays showed that several cytokines, including MMP-8, TIMP-1, MCP-1 and ICAM-1, were significantly upregulated in the vehicle-treated allogeneic group versus controls. Thalidomide reduced expression levels of MMP-8 (P < 0.05) and MCP-1 (P < 0.01), cytokines associated with tissue remodelling and inflammation, respectively. Reduction of these cytokines may be indicative of thalidomide's mechanism of action: decreased tissue remodelling, as seen in our histological results, as well as reduced post-transplant inflammation. 
No significant side effects caused by thalidomide treatment in rats
We tested the safety of thalidomide after allogeneic orthotopic aortic transplants. Animals treated with thalidomide showed no obvious signs of discomfort or distress. Blood samples from vehicle-treated (n = 3) or thalidomide-treated (n = 7) animals showed no significant differences in biomarkers of kidney function (BUN, creatinine), serum cholesterol and triglyceride levels (cholesterol, triglyceride, LDL, HDL), liver function (ALT, AST) or whole blood count (RDW, Leucocyte, PLT, Hb, Hct, RBC, MCV, MCH, MCHC) (Fig. S1 ).
Thalidomide treatment does not attenuate lymphocyte activity in acute transplant rejection model
As our data support thalidomide as a potential therapy for CAV, we aimed to clarify whether the success of thalidomide treatment was due to a general reduction in graft rejection or whether it was specific to chronic rejection. Thus, we tested the effect of thalidomide treatment in heterotopic heart transplantation, an accepted rodent model for acute transplant rejection [15] . Syngeneic (Lew:Lew) or allogeneic (BN:Lew) transplantation was performed (Fig. S2a) . Allogeneic transplant recipients received either vehicle control or thalidomide post-transplant. At 6 days postoperation (POD6), splenocytes were collected for ELISpot and mixed lymphocyte reaction (MLR) assays.
IFNc levels -a proxy for systemic lymphocyte activation -were measured by ELISpot. In contrast to the dramatic effects of thalidomide in our chronic rejection model, thalidomide treatment did not appear to affect IFNc production in our acute rejection model (Fig. S2b) . Similarly, no alterations in lymphocyte proliferation were found by our MLR assay (Fig. S2c) . These data suggest that thalidomide may be a specific treatment for chronic rejection, as it does not appear to be beneficial for reduction of acute rejection.
The primary pathology in CAV is coronary vessel intimal thickening; thus, reducing luminal obliteration would be highly advantageous to the long-term survival of transplant recipients.
Discussion
Cardiac allograft vasculopathy is a leading cause of late death for cardiac transplant recipients and has remained resistant to therapeutic interventions. The identification of thalidomide as an immunomodulatory agent suggests its potential use in preventing graft rejection. Thalidomide has been described as having anticytokine, antiintegrin and antiangiogenic properties [17] , and has beneficial effects in other proliferative diseases, including as a treatment for idiopathic pulmonary fibrosis, bone marrow transplantation, skin allograft transplantation and heterotopic heart transplantation [12, 18, 19] . As thalidomide's complete mechanism of action is yet unclear, we have investigated the pathophysiological effects of thalidomide in a rat aortic model of CAV. In this model, analysis of histopathological specimens is drastically facilitated as transplant vasculopathy may be examined in one single vessel of a sole defined diameter instead of the exploration of numerous small cardiac vessels showing a vast variety in size in the heterotopic heart transplant model. Indeed, the immune response generated by an aortic allograft is sufficient to trigger chronic alterations in the transplant [20] .
Our data suggest that thalidomide dramatically reduces luminal narrowing in an established rat model of CAV. Immunohistochemical analysis showed that loss of medial differentiated SMCs -a hallmark of CAV -was prevented by thalidomide treatment. Furthermore, thalidomide prevented dedifferentiation and intimal proliferation of SMCs. Our results are supported by recent literature showing beneficial effects of thalidomide in rat models of transplant arteriosclerosis and hereditary haemorrhagic telangiectasia [13, 21] .
Because the molecular mechanism of thalidomide is not yet clear, we generated an intragraft cytokine profile, showing that thalidomide significantly reduced expression of MMP-8 and MCP-1. Zhang et al. [13] used immunohistochemistry and Western blot to suggest that thalidomide alters VEGF, PDGF and ICAM-1 levels, whereas we found no significant alteration in these molecules using the more accurate ELISpot and MLR assays. This difference in observation is likely due to the fact that Zhang et al. used a high responder transplantation model (BN:Lew) in their assays, which does not accurately represent CAV, while we used a more appropriate low responder model (F344:Lew) to simulate chronic rejection.
Matrix metalloproteases (MMPs) are zinc enzymes involved in extracellular matrix turnover. Interestingly, increased MMP expression levels have been connected with intimal thickening [22] and increased levels of MMP-2 and MMP-9 have been associated with chronic graft rejection [22] . MMP-8 itself appears to largely be produced by neutrophils and is upregulated within the first few weeks post-transplantation [23] . Furthermore, general inhibition of MMPs prevents migration and proliferation of SMCs in CAV [24] . An MMP inhibitor that has been shown to reduce levels of MMP-8 was also linked to attenuation of CAV [24] . This is consistent with our findings, which show downregulation of MMP-8 associated with thalidomide treatment and reduced SMC proliferation and dedifferentiation.
Intragraft cytokine MCP-1 levels were also significantly reduced by thalidomide treatment. The literature surrounding MCP-1's function supports this data. Monocyte chemotactic protein-1 (MCP-1) is associated with inflammatory responses, namely recruiting monocytes, memory T cells and dendritic cells to places of inflammation. Reduced levels of MCP-1 have been correlated with reduction of neointimal hyperplasia [25, 26] and decreased chronic cardiac rejection [27] .
Because of thalidomide's previously identified teratogenic effects [7] , it was vital that we examine the potential side effects of thalidomide treatment. As seen with previous approval of thalidomide for treatment of erythema nodosum leprosum, we found no significant side effects to our thalidomide treatment in rats. However, the study period was only 28 days, thus lacking long-term data for safety and toxicity of thalidomide.
Finally, to further elucidate thalidomide's function, we wanted to clarify whether the effect we saw was specific to CAV or due to general immunogenic suppression. We examined whether thalidomide affected the pathogenic pathways associated with acute transplant rejection, namely T lymphocyte activation and proliferation. In contrast to the dramatic effects seen on CAV pathophysiology, we did not see significant inhibition of lymphocyte activation or proliferation. This leads us to conclude that thalidomide likely does not reduce CAV via prevention of generalized immune activation, but rather through a different, more specific mechanism of action on the vascular wall.
In conclusion, we demonstrate that thalidomide treatment dramatically reduces CAV in a well-established rat model of chronic rejection, preventing the intimal proliferation and the loss of medial differentiated SMCs that are hallmarks of CAV. Thalidomide is therefore potentially useful in clinical applications to prevent CAV after human heart transplantation.
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